Virus-like nanoparticle vaccine effective against RSV
RSV, a respiratory virus, infects the breathing passages and lungs. It is responsible for major health concerns in elderly adults and infants. RSV is the main cause of bronchiolitis, which is the inflammation of the lung’s small airways. Children under one year old within the U.S. develop pneumonia from RSV infections. Elderly adults with respiratory illness typically contract these illnesses from RSV.
These results show that the RSV vaccine, with virus-like nanoparticles that are genetically engineered, microscopic particles, could provide people with long-term protection against infections of RSV. It could also be an innovative treatment options for patients who have RSV.
The subject involved mice that received a series of vaccinations. One year after receiving the vaccine, these mice were administered with live pathogens of RSV. The mice with the FG VLPs vaccine had no obvious signs of developing severe pulmonary disease.
"Recombinant engineered nanoparticle vaccines might be developed to prevent highly contagious respiratory pathogens such as RSV, as reported in this study," Dr. Sang-Moo Kang, a professor in the Institute for Biomedical Sciences at Georgia State, said.
As of today, there is no licensed vaccine for RSV.
Further details are available in the July 14 edition of the International Journal of Nanomedicine.